A Phase 3b study to evaluate the long-term outcomes following treatment with Abbvie DAAs and with or without Ribavirin (RBV) in adults with genotype 1 Chronic Hepatitis C Virus (HCV) Infection
The purpose of this study is to evaluate Long-term Outcomes following treatment with ABT-450/r/ABT-267, ABT-333 with or without RBV in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection.
Trial Website: https://clinicaltrials.gov/show/NCT02167945
Are you Eligible? (Inclusion Criteria)
Inclusion Criteria:
- Females must be post-menopausal for more than 2 years or surgically sterile or practicing specific forms of birth control
- Chronic hepatitis C, genotype 1-infection (HCV RNA level greater than 1,000 IU/mL at screening)
- HCV genotype 1 infection per screening laboratory result
Exclusion Criteria:
- Use of contraindicated medications within 2 weeks of dosing
- Abnormal laboratory tests
- Positive hepatitis B surface antigen and anti-Human Immunodeficiency Virus Antibody
- Clinical history of liver decompensation
- Presence of hepatocellular carcinoma at screening
Specialty Area(s)
Liver